Literature DB >> 21696297

PTEN, pAKT, and pmTOR expression and subcellular distribution in primary renal cell carcinomas and their metastases.

Martina Hager1, Heike Haufe, Lukas Lusuardi, Nikolaus Schmeller, Christian Kolbitsch.   

Abstract

The present study evaluated pAKT, pmTOR, and PTEN expression in a tissue microarray of primary renal cell carcinomas (PRCCs), their metastases, and normal renal parenchyma (NRP) (N = 45) by means of immunohistochemistry. Metastases in most subcellular compartments showed comparable and stronger expression for pAKT, pmTOR, and PTEN than PRCC and NRP, which was even more pronounced in patients with high-risk Memorial Sloan-Kettering Cancer Center (MSKCC) score. Furthermore, most subcellular compartments showed no differences between lymphogenous, haematogenous, synchronous, and metachronous metastases, which is interesting with regard to sensitivity to mTOR inhibitor therapy in metastasized RCCs with alterations in the PI3K/AKT pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21696297     DOI: 10.3109/07357907.2011.584782

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  6 in total

1.  mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.

Authors:  Steffen Rausch; Daniel Schollenberger; Joerg Hennenlotter; Viktoria Stühler; Stephan Kruck; Arnulf Stenzl; Jens Bedke
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-27       Impact factor: 4.553

2.  FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.

Authors:  James L Chen; Daniel E Appelbaum; Masha Kocherginsky; Charles L Cowey; Wendy Kimryn Rathmell; David F McDermott; Walter M Stadler
Journal:  Cancer Med       Date:  2013-07-10       Impact factor: 4.452

3.  Clinical significance of aberrant mammalian target of rapamycin expression in stage IIIB colon cancer.

Authors:  Meiling Wen; Baoxiu Li; Xiaofei Cao; Chengyin Weng; Yong Wu; Xisheng Fang; Xiaoshi Zhang; Guolong Liu
Journal:  Oncol Lett       Date:  2014-06-25       Impact factor: 2.967

4.  Phosphorylated mTOR Expression Profiles in Human Normal and Carcinoma Tissues.

Authors:  Hojung Lee
Journal:  Dis Markers       Date:  2017-07-31       Impact factor: 3.434

5.  MicroRNA-106a regulates autophagy-related cell death and EMT by targeting TP53INP1 in lung cancer with bone metastasis.

Authors:  Lei Han; Zeyong Huang; Yan Liu; Lijuan Ye; Dongqi Li; Zhihong Yao; Cao Wang; Ya Zhang; Hang Yang; Zunxian Tan; Jiadai Tang; Zuozhang Yang
Journal:  Cell Death Dis       Date:  2021-10-30       Impact factor: 8.469

6.  Prognostic significance of PI3K/AKT/ mTOR signaling pathway members in clear cell renal cell carcinoma.

Authors:  Demin Fan; Qiang Liu; Fei Wu; Na Liu; Hongyi Qu; Yijiao Yuan; Yong Li; Huayu Gao; Juntao Ge; Yue Xu; Hao Wang; Qingyong Liu; Zuohui Zhao
Journal:  PeerJ       Date:  2020-06-01       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.